HUTCHISON CHINA/S (HCM) Shares Bought by Bellevue Group AG

Bellevue Group AG raised its stake in HUTCHISON CHINA/S (NASDAQ:HCM) by 10.0% in the 2nd quarter, HoldingsChannel reports. The firm owned 332,536 shares of the company’s stock after acquiring an additional 30,116 shares during the quarter. Bellevue Group AG’s holdings in HUTCHISON CHINA/S were worth $10,023,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Royal Bank of Canada bought a new stake in HUTCHISON CHINA/S in the first quarter valued at $199,000. Geode Capital Management LLC bought a new stake in shares of HUTCHISON CHINA/S during the fourth quarter worth about $258,000. Citadel Advisors LLC bought a new stake in shares of HUTCHISON CHINA/S during the first quarter worth about $286,000. Pendal Group Ltd bought a new stake in shares of HUTCHISON CHINA/S during the first quarter worth about $501,000. Finally, DekaBank Deutsche Girozentrale bought a new stake in shares of HUTCHISON CHINA/S during the first quarter worth about $866,000. 9.81% of the stock is owned by hedge funds and other institutional investors.

NASDAQ:HCM opened at $31.05 on Wednesday. The company has a quick ratio of 4.55, a current ratio of 4.67 and a debt-to-equity ratio of 0.06. The stock has a market cap of $4.37 billion, a PE ratio of -141.14 and a beta of 0.12. HUTCHISON CHINA/S has a one year low of $22.90 and a one year high of $42.25.



Several equities research analysts have recently commented on the stock. BidaskClub raised shares of HUTCHISON CHINA/S from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, July 25th. MED assumed coverage on shares of HUTCHISON CHINA/S in a research report on Monday, July 23rd. They set a “positive” rating for the company. Zacks Investment Research raised shares of HUTCHISON CHINA/S from a “sell” rating to a “hold” rating in a research report on Tuesday, May 15th. Finally, ValuEngine raised shares of HUTCHISON CHINA/S from a “hold” rating to a “buy” rating in a research report on Wednesday, May 2nd. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $38.00.

HUTCHISON CHINA/S Company Profile

Hutchison China MediTech Limited, a biopharmaceutical company, engages in the research, development, manufacture, and sale of pharmaceuticals and healthcare products primarily in the People's Republic of China and Hong Kong. It operates through Innovation Platform and Commercial Platform segments.

Featured Article: Technical Analysis

Want to see what other hedge funds are holding HCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HUTCHISON CHINA/S (NASDAQ:HCM).

Institutional Ownership by Quarter for HUTCHISON CHINA/S (NASDAQ:HCM)

Receive News & Ratings for HUTCHISON CHINA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHISON CHINA/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply